DI
MYGN icon

Disciplined Investments’s Myriad Genetics MYGN Stock Holding History

Disciplined Investments’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11
Closed -$255 – 1029
2023
Q2 		$255 Buy
11
+2
+22% +$44 ﹤0.01% 1442
2023
Q1 		$209 Buy
9
+1
+13% +$20 ﹤0.01% 1472
2022
Q4 		$116 Sell
8
-2
-20% -$37 ﹤0.01% 1519
2022
Q3 		$0 Buy
10
+7
+233% +$161 ﹤0.01% 1468
2022
Q2 		$0 Sell
3
-3
-50% -$62 ﹤0.01% 1496
2022
Q1 		$0 Buy
+6
New +$154 ﹤0.01% 1520

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Disciplined Investments's MYGN Position: Q3 2023 in Review

Disciplined Investments sold out of Myriad Genetics (MYGN) in Q3 2023, closing a stake of 11 shares — an estimated $255 sold.

Disciplined Investments first reported a position in MYGN in Q1 2022 and held it in 6 quarters. The position peaked at $255 in Q2 2023. 186 funds tracked by Wall St. Rank hold MYGN as of Q3 2023.

  • Disciplined Investments reported no remaining Myriad Genetics position as of Q3 2023 after selling out during the quarter.
  • Disciplined Investments sold 11 Myriad Genetics shares in Q3 2023, an estimated $255.
  • Disciplined Investments first reported a position in Myriad Genetics in Q1 2022 and held it in 6 quarters.
  • Disciplined Investments's Myriad Genetics position peaked at $255 in Q2 2023.
  • 186 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2023.

Based on Disciplined Investments's 13F filing for Q3 2023, filed 14 Nov 2023.